**Core Concept**
Mesna is a medication used in conjunction with certain chemotherapeutic agents, such as cyclophosphamide, to prevent hemorrhagic cystitis. Hemorrhagic cystitis is a potential side effect of these drugs, which can cause bleeding and inflammation in the bladder.

**Why the Correct Answer is Right**
Mesna works by conjugating with acrolein, a toxic metabolite of cyclophosphamide that is responsible for causing hemorrhagic cystitis. By forming a conjugate with acrolein, mesna prevents its interaction with the bladder mucosa, thereby reducing the risk of hemorrhagic cystitis. This mechanism is particularly important in patients receiving high-dose cyclophosphamide, as it can significantly reduce the incidence of this side effect.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because mesna is not typically used to prevent nausea and vomiting associated with chemotherapy. Other medications, such as ondansetron, are more commonly used for this purpose.
**Option B:** This option is incorrect because mesna does not have a significant role in reducing the myelosuppressive effects of cyclophosphamide. Myelosuppression is a common side effect of chemotherapy, but mesna is not the primary medication used to prevent it.
**Option C:** This option is incorrect because mesna is not used to enhance the antineoplastic effects of cyclophosphamide. While mesna is often administered concurrently with cyclophosphamide, its primary purpose is to prevent a specific side effect, rather than to enhance the drug's anticancer activity.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that mesna is typically administered in two doses: one dose before and another dose 4-6 hours after the administration of cyclophosphamide. This dosing schedule is critical in preventing hemorrhagic cystitis and ensuring the optimal efficacy of mesna.

**Correct Answer: D. To prevent hemorrhagic cystitis.**